Muscle Relaxants in Patients with Renal or Hepatic Failure

  • P. Duvaldestin
Conference paper


Most of factors which alter the duration of intensity of action of muscle relaxants have a pharmacokinetic origin. A few have a pharmacodynamic origin.


Renal Failure Chronic Renal Failure Biliary Atresia Plasma Cholinesterase Pancuronium Bromide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agoston S., Vermeer GA., Kersten UW., Meijer DKF. The fate of pancuronium bromide in man. Acta Anaesthesiol Scand 17: 267–275, 1973PubMedCrossRefGoogle Scholar
  2. Agoston S., Vermeer GA., Kersten UW. and Scaf AHJ. A preliminary investigation of the renal and hepatic excretion of gallamine triethiodide in man. Br J Anaesth 50: 345–351, 1978PubMedCrossRefGoogle Scholar
  3. Agoston, S., Vandenbrom RHG., Wierda JMKH., Houvertjes MC. and Kersten UW. Pharmacokinetics and disposition of pipecuronium bromide in the cat. Eur J Anaesth 5: 233–242,1988Google Scholar
  4. Arden JR., Lynam DP., Castagnoli KP., Canfell C., Cannon JC. and Miller RD. Vecuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis. Anesthesiology 68: 771–776, 1988PubMedCrossRefGoogle Scholar
  5. Badragi L., Feher T., Varadi A. and Vereczkey L. Pharmacokinetics of pipecuronium bromide in the rat. Arzneimittel Forschung 30: 366–370, 1980Google Scholar
  6. Basta SJ., Savarese JJ. and Ali HH. Clinical pharmacology of doxacurium chloride (BW A 938U): a new long acting depolarizing muscle relaxant. Anesthesiology 69: 472–486,1988CrossRefGoogle Scholar
  7. Bell CF., Hunter JM., Jones RS. and Utting JE. Use of atracurium and vecuronium in patients with oesophageal varices. Br J Anaesth 57: 160–168, 1985PubMedCrossRefGoogle Scholar
  8. Bencini AF., Scaf AHJ., Sohn YL., Kersten UW. and Agoston S. Clinical pharmacokinetics of vecuronium. In Clinical Experience with Norcuron. (ed. Agoston S., Bowman WC., Miller RD. and Viby-Mogensen J.) pp 115–123, Elsevier, Amsterdam, 1983Google Scholar
  9. Bencini AF., Scaf AHJ., Sohn YL., Meistelman C., Liehnart A., Kersten UW. et al. Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure. Anesth Analg 65: 245251, 1986aCrossRefGoogle Scholar
  10. Bencini AF., Scaf AHJ., Sohn YL., Meistelman C., Liehnart A., Kersten Kleef UW. and Agoston S. Hepatobiliary disposition of vecuronium in patients with cholestasis. Br J Anaesth 58: 988–995, 1986bCrossRefGoogle Scholar
  11. Bevan DR., Donati F., Gyasi H. and Williams A. Cumulation of vecuronium in renal failure. Anesthesiology 61: A296, 1984CrossRefGoogle Scholar
  12. Brotherton WP. and Matteo RS. Pharmacokinetics of metocurine in man with renal failure. Anesthesiology 53, S268, 1980CrossRefGoogle Scholar
  13. Buzello W. and Ruthven-Murray J. Der Konzentrationsverlauf von pancuronium im serum anurischer patienten. Anaesthesist 25: 440–443, 1976PubMedGoogle Scholar
  14. Caldwell JE., Canfell PC., Castagnoli KP., Lynam DP., Fahey MR., Fischer DM. et al. The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. Anesthesiology 70: 7–12, 1989PubMedCrossRefGoogle Scholar
  15. Cashman JN., Luke JJ. and Jones RM. Neuromuscular block with doxacurium (BW A 938U) in patients with normal or absent renal function. Br J Anaesth 64: 186–192, 1990PubMedCrossRefGoogle Scholar
  16. Cook DR., Brandom BS., Stiller RL., Woelel S., Lair A. and Slater J. Pharmacokinetics of atracurium in normal and liver failure patients. Anesthesiology 61: A423, 1984CrossRefGoogle Scholar
  17. Cook DR., Freeman JA., Lai AA., Robertson KA., Kang Y., Stiller RL. et al. Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. Anesth Analg 72: 145–150, 1991PubMedCrossRefGoogle Scholar
  18. Cozanitis D. and Haapanen E. Studies on muscle relaxants during haemodialysis. Acta Anaesthesiol Scand 23: 225–234, 1979PubMedCrossRefGoogle Scholar
  19. De Bros F., Lai A., Scott R., De Bros J., Goudsouzian N. and Ali HH. Pharmacokinetics and pharmacodynamics of atracurium during isoflurane anaesthesia in normal and anephric patients. Anaesth Analg 65: 743–746, 1986Google Scholar
  20. Desmonds JW. and Gordon RA. The effect of haemodialysis on blood volume and plasma cholinesterase levels. Can Anaesth Soc J 16: 292–301, 1969CrossRefGoogle Scholar
  21. D’Hollander AA., Camu F. and Sanders M. Comparative evaluation of neuromuscular blockade after pancuronium administration in patients with and without renal failure. Acta Anaesthesiol Scand 22: 21–26, 1978PubMedCrossRefGoogle Scholar
  22. D’Honneur G., Khalil M., Dominique C., Haberer JP., Kleef UW. and Duvaldestin P. Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. Anesth Analg 77:1203–1206, 1993PubMedCrossRefGoogle Scholar
  23. Dresner DC., Basta SJ., Ali HH., Schwartz AF. and Embree PB. Pharmacokinetics and pharmacodynamics of atracurium in young and elderly patients during isoflurane anesthesia. Anesth Analg 71: 498–502, 1990PubMedCrossRefGoogle Scholar
  24. Dundee JW. and Gray TC. Resistance to d-tubocurarine chloride in the presence of liver drainage. Lancet ii 16–17, 1953Google Scholar
  25. Duvaldestin P. and Henzel D. Binding of tubocurarine, fazadinium, pancuronium and ORG NC45 to serum proteins in normal man and in patients with cirrhosis. Br J Anaesth 54: 513–516, 1982PubMedCrossRefGoogle Scholar
  26. Duvaldestin P., Agoston S., Henzel D., Kersten UW. and Desmonts JM. Pancuronium pharmacokinetics in patients with liver cirrhosis. Br J Anaesth 50: 1131–1136, 1978PubMedCrossRefGoogle Scholar
  27. Duvaldestin P., Lebrault C. and Chauvin M. Pharmacokinetics of muscle relaxants in patients with liver disease. Clin in Anaesthesiol 3: 293–306, 1985Google Scholar
  28. Fahey MR., Maris RB., Miller RD., Nguyen TL. and Upton RA. Pharmacokinetics of ORG NC 45 (Norcuron) in patients with and without renal failure. Br J Anaesth 53: 1049–1052, 1981PubMedCrossRefGoogle Scholar
  29. Fahey MR., Rupp SM., Fischer D., Miller RD., Sharma M., Canfell C. et al. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 61: 699–702, 1984PubMedCrossRefGoogle Scholar
  30. Feldman SA. and Levy JZ. Prolonged paresis following gallamine. Br J Anaesth 35: 804–806,1963PubMedCrossRefGoogle Scholar
  31. Feldman SA., Cohen EN. and Golling RC. The excretion of gallamine in dog. Anesthesiology 30: 593–598, 1969PubMedCrossRefGoogle Scholar
  32. Gilbaldi M., Levy G. and Hayton WL. Tubocurarine and renal failure. Br J Anaesth 44: 163–165, 1972CrossRefGoogle Scholar
  33. Haselhuhn DH. The use of pentothal in the presence of severe hepatic disease. Anaesth Analg 36: 73–75, 1957Google Scholar
  34. Hennis PJ., Fahey MR., Canfell PC., Shi WZ and Miller RD. Pharmacology of laudanosine in dogs. Anesthesiology 65: 56–60, 1986PubMedCrossRefGoogle Scholar
  35. Hunter JM., Parker CJR., Bell CF., Jones RS. and Utting JE. The use of different doses of vecuronium in patients with liver dysfunction. Br J of Anaesthesia 57: 758–764,1985CrossRefGoogle Scholar
  36. Kent AP., Parker CJR. and Hunter JM. Pharmacokinetics of atracurium and laudanosine in the elderly. Br J Anaesth 63: 661–666, 1989PubMedCrossRefGoogle Scholar
  37. Khalil M., D’honneur G., Duvaldestin P., Slavov V., De Hys C., Gomeni P. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. Anesthesiology 80: 1241–1247, 1994PubMedCrossRefGoogle Scholar
  38. Khuenl-Brady K., Canfell PC., Miller RD., Castagnoli KP. and Agoston S. Pharmacokinetics and disposition of ORG 9416 and ORG 9426 in cat. Br J Anaesth 62: 225–226, 1989Google Scholar
  39. Khuenl-Brady K., Castagnoli KP., Canfell PC., Caldwell JE., Agoston S. and Miller RD. The neuromuscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat. Anesthesiology 72: 669–674, 1990PubMedCrossRefGoogle Scholar
  40. Kitts JB., Fischer DM, Canfell CP., Spellman BA. and Caldwell JE. Pharmacokinetics and pharmacodynamics of atracurium in the elderly. Anesthesiology 72: 272–275, 1990PubMedCrossRefGoogle Scholar
  41. Lebrault C., Lavaud E., Strumza P., Nebout T. and Duvaldestin P. Effet myorelaxant de l’atracurium chez les patients insuffisants rénaux chroniques. Ann Fr Anesth Réanim 3: 273–276, 1984PubMedCrossRefGoogle Scholar
  42. Lebrault C., Berger JL., D’Hollander AA., Gomeni R., Henzel D. and Duvaldestin P. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. Anesthesiology 62: 601–605, 1985PubMedCrossRefGoogle Scholar
  43. Lebrault C., Duvaldestin P., Henzel D., Chauvin M. and Guesnon P. Pharmacokinetics and pharmacodynamics of vecuronium in patients with cholestasis. Br J Anaesth 58: 983–987, 1986PubMedCrossRefGoogle Scholar
  44. Lee JA and Atkinson RS. In Synopsis of Anaesthesia. 7th edn (ed.J.A. Lee and R.S. Atkinson) John Wright and Sons, p.312, Bristol, 1973Google Scholar
  45. Lien CA., Matteo RS., Ornstein E., Schwartz AE. and Diaz J. Distribution, elimination and action of vecuronium in elderly. Anesth Analg 73: 39–42, 1991PubMedCrossRefGoogle Scholar
  46. Lowenstein E., Goldfine C. and Flacke WE. Administration of gallamine in the presence of renal failure, reversal of neuromuscular blockade by pertioneal dialysis. Anesthesiology, 33: 556–558,1970PubMedCrossRefGoogle Scholar
  47. Lynam DP., Cronnelly R., Castagnoli KP., Canfell C., Caldwell J. and Arden J. The pharmacodynamics, pharmacokinetics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure. Anesthesiology 69: 227–31, 1988PubMedCrossRefGoogle Scholar
  48. Magorian T., Wood P., Caldwell JE., Szenohradszky J., Segredo V., Sharma H. et al. Pharmacokinetics, onset, duration of action of rocuronium in humans: normal vs hepatic dysfunction. Anesthesiology 75: A 1069,1991CrossRefGoogle Scholar
  49. McLeod K., Watson MJ. and Rawlins MD. Pharmacokinetics of pancuronium in patients with normal and impaired renal function. Br J Anaesth 48: 341–345, 1976PubMedCrossRefGoogle Scholar
  50. Meijer DKF., Waitering JG. and Vonk RJ. Hepatic uptake, biliary excretion of dtubocurarine and trimethyl-tubocurarine in the rat in vivo. and in isolated perfused rat livers. J Pharmacol Exp Ther 198: 229–239, 1976PubMedGoogle Scholar
  51. Meijer DKF. and Scaf AHJ. Inhibition of the transport of d-tubocurarine from blood to the bile by strophantoside-K in the isolated perfused rat liver. Eur J Pharmacol 4: 343–346, 1968CrossRefGoogle Scholar
  52. Meijer DKF, Weitering JG., Vermeer GA. and Scaf AHI. Comparative pharmacokinetics of d-tubocurarine, metocurine in man. Anesthesiology 51: 402–407,1979PubMedCrossRefGoogle Scholar
  53. Miller RD., Stevens WC., and Way WL. The effect of renal failure and hyperkalaemia on the duration of pancuronium neuromuscular blockade in man. Anesth Analg 52: 661–666, 1973PubMedGoogle Scholar
  54. Miller RD., Matteo RS., Benet LZ. and Sohn YJ. The pharmacokinetics of d-tubocurarine in man with and without renal failure. J Pharmacol Exp Ther 202: 1–7,1977PubMedGoogle Scholar
  55. Mongin-Long D., Chabrol B., Baude C., Ville D., Renaudie M., Dubernard JM. et al. Atracurium in patients with renal failure. Br J Anaesth 58: 449, 1986CrossRefGoogle Scholar
  56. Nguyen HD., Kaplan R., Nagashima H., Duncalf D. and Foldes FF. The neuromuscular effect of atracurium in anephric patients. Anesthesiology 63: A 335, 1985CrossRefGoogle Scholar
  57. Raaflaub J. and Frey P. Zur Pharmacokinetik von diallynortoxiferin beim Mernschen. Arzneimittel Forschung Drug Research 22: 73–78, 1972Google Scholar
  58. Ramzan MI., Shanks CA. and Triggs EJ. Pharmacokinetics and pharmacodynamics of gallamine triethiodide in patients with total biliary obstruction. Anesth Analg 60: 289–296, 1981aGoogle Scholar
  59. Ramzan MI., Shanks CA. and Triggs EJ. Gallamine disposition in surgical patients with chronic renal failure. Br J Clin Pharmacol 12: 141–147, 1981bGoogle Scholar
  60. Reidenberg MM and Drayer DE. Alteration of drug-protein binding in renal disease. Clin Pharmacokinet 9: 18–26, 1984PubMedCrossRefGoogle Scholar
  61. Robertson GS. Serum cholinesterase deficiency. I: disease, inheritance. Br J Anaesth 38: 355–360, 1966PubMedCrossRefGoogle Scholar
  62. Ryan DW. Preoperative serum cholinesterase concentration in chronic renal failure. Br J Anaesth 46: 945–949, 1977CrossRefGoogle Scholar
  63. Savarese JJ., Ali HH., Basta SJ., Embree PB., Scott RPF., Seinder W. et al. The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). Anesthesiology 68: 723–732, 1988aCrossRefGoogle Scholar
  64. Savarese JJ., Wastila WB., El Sayad HA., Ali HH., Basta SJ. and Embree PB. Some preliminary aspects of the basic clinical pharmacology of mivacurium (BW 1090U) and doxacurium (BW A 938U) a preliminary report. In:Recent developments in muscle relaxation: atracurium in perspective. (ed. R.M. Jones, J.P. Payne) pp 55–60, Royal Society of Medicine, London, 1988bGoogle Scholar
  65. Savarese JJ. Clinical properties of the new relaxants: update. Acta Anaesthesiol Scand 33 (suppl91) 97–98,1989Google Scholar
  66. Sheiner LB., Stanski DR., Vozeh S., Miller RD. and Ham J. Simultaneous modeling of pharmacokinetics, pharmacodynamics application to d-tubocurarine. Clin Pharmacol Ther 25: 358–371, 1979PubMedGoogle Scholar
  67. Simpson DA and Green DW. Use of atracurium during major abdominal surgery in infants with hepatic dysfunction from biliary atresia. Br J Anaesth 58: 1214–1217,1986PubMedCrossRefGoogle Scholar
  68. Singer MM., Eutton R. and Way WL. Untoward results of gallamine administration during bilateral nephrectomy: treatment with haemodialysis. Br J Anaesth 43: 404–405, 1971PubMedCrossRefGoogle Scholar
  69. Somogyi AA., Shanks CA. and Triggs EJ. The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide. Eur J Clin Pharmacol 12: 23–29, 1977aCrossRefGoogle Scholar
  70. Somogyi AA., Shanks CA. and Triggs EJ. Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. Br J Anaesth 49: 1103–1108, 1977bCrossRefGoogle Scholar
  71. Stovner J. Proetin binding. In: Recent progress in anaesthesiology and resuscitation.(ed. I. M. Arias) pp 238–240, Elsevier, Amsterdam, 1975Google Scholar
  72. Stovner J., Theodorsen I. and Bjelke E. Sensitivity to tubocurarine and alcuronium with special reference to plasma protein pattern. Br J Anaesth 43: 385–391,1971PubMedCrossRefGoogle Scholar
  73. Szenohradszky J., Segredo V., Caldwell JE., Sharma M., Gruenke ID. and Miller RD. Pharmacokinetics, onset, and duration of action of ORG 9426 in humans: normal vs absent renal function. Anesth Analg 72: S290, 1991Google Scholar
  74. Thomas JL. and Holmes JH. Effect of hemodialysis on plasma cholinesterase. Anesth Analg 49: 323–325, 1970PubMedGoogle Scholar
  75. Vonk RJ, Scholtens E., Keulemans GTP. and Meijer DKF. Choleresis and transport mechanisms. IV. Influence of bile salt choleresis on the hepatic transport of the organic cations d-tubocurarine, and N-acetylprocaine ethobromide. Naunyn-Schmiedebergs Arch Exp Pharmacol 302: 1–7, 1978CrossRefGoogle Scholar
  76. Ward ME., Adu-Gyamfi Y. and Strunin L. Althesin and pancuronium in chronic liver disease. Br J Anaesth 47: 1199–1204,1975PubMedCrossRefGoogle Scholar
  77. Ward S. and Neill EAM. Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). Br J Anaesth 55: 1169–72, 1983PubMedCrossRefGoogle Scholar
  78. Ward S., Boheimer N., Weatherley BC. and Williams SG. The effect of renal impairment on the disposition of atracurium and its breakdown products. Anesthesiology 63: A 337, 1985Google Scholar
  79. White RD., de Weerd JH. and Dawson B. Gallamine in anaesthesia for patients with chronic renal failure undergoing bilateral nephrectomy. Anaesth Analg 50: 11–16,1971CrossRefGoogle Scholar
  80. Wierda JMKH., Szenohradszky J., de Wit APM., Zentai G., Agoston S., Kakas M. et al. The pharmacokinetics urinary and biliary excretion of pipecuronium bromide (Arduan). Eur J Anaesthesiol 8: 451–457, 1991PubMedGoogle Scholar
  81. Wood M. Plasma drug binding: implications for anesthesiologist. Anesth Analg 65: 786–804,1986PubMedGoogle Scholar
  82. Wood M., Stone WJ. and Wood AJJ. Plasma binding of pancuronium: effects of age, sex and disease. Clin in Anaesthesiol 3: 293–306, 1985Google Scholar

Copyright information

© Springer Japan 1995

Authors and Affiliations

  • P. Duvaldestin
    • 1
    • 2
  1. 1.Hopital Henri MandorCretell cedexFrance
  2. 2.ParisFrance

Personalised recommendations